Allergy Therapeutics peanut vaccine shows strong immune response in early trial
AIM-listed biotech reports biomarker results suggesting its VLP Peanut treatment could work in as few as three injections Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the AIM-listed allergy immunotherapy company, has reported positive biomarker results from its PROTECT Phase I/IIa trial of VLP Peanut, a virus-like particle (VLP) vaccine designed to treat peanut allergy. The data showed a strong and consistent immune response across all trial participants, with higher doses associated with greater reductions in basophil sensitivity, a measure of how reactive immune cells are to allergens.
Buccaneer Energy seals funding as it looks to boost oil production
Buccaneer Energy Plc (AIM:BUCE, FRA:LMU1) confirmed to investors it has closed a £350,000 fundraise to finance an adjacent producing-well acquisition in East Texas and push ahead with an Organic Oil Recovery (OOR) programme that it says has already doubled output in a pilot area. The AIM-quoted group issued new shares priced at 0.01p, with participation from institutional investor Premier Miton, alongside directors, management and existing shareholders.
Allergy Therapeutics reports positive data across grass pollen and peanut allergy programmes
The AIM-listed immunotherapy specialist will present three posters at the AAAAI Annual Meeting in Philadelphia this week Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the AIM-listed biotechnology company specialising in allergy treatments, said it would present positive clinical and safety data from across its research portfolio at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia. The company's flagship grass pollen treatment, Grass MATA MPL, delivered a statistically significant 22.5% improvement in a combined symptom and medication score compared with placebo across two phase III clinical trials.
TomCo Energy agrees new Valkor deal and raises some working capital, shares drop
TomCo Energy PLC (AIM:TOM, OTC:TMCGF) shares dropped 35% on Monday, falling to 0.035p, impacted by expected new equity dilution, after it announced a renewed partnership with Valkor LLC that leaves the pair jointly controlling Greenfield Energy on a 50:50 basis, as the AIM-listed group looks to progress oil-sands opportunities in Utah's Uinta Basin. The reset comes with balance-sheet engineering.
Rome Resources unearths "exciting new areas" for tin and copper at Mont Agoma
Rome Resources Plc (AIM:RMR, FRA:33R) has sharpened drill targeting at its Mont Agoma prospect in the Democratic Republic of Congo after a new geological interpretation outlined fresh, high-priority zones for both tin and copper beyond the current footprint. The AIM-listed explorer said specialist consultancy Chemostrat reworked its geological and assay database and identified a marker horizon above “Zone 3” that better predicts where mineralisation sits, splitting the sequence into five zones.
Seeing Machines flags second-half profit as EU car safety deadline nears
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z), the AIM-listed computer vision technology company, said it expected automotive production volumes to “increase materially” in the coming quarters as the EU's General Safety Regulation deadline approaches. In the update, it also forecast positive adjusted earnings before interest, tax, depreciation and amortisation in the third quarter and the second half of its financial year.
Cora Gold shares fall 12% after it unveils fundraiser for Mali project
Shares in West African explorer Cora Gold Ltd (AIM:CORA, FRA:C0J) dropped sharply after the company secured up to £15.7 million in new funding to advance its flagship mine in Mali towards production. Cora, which trades on London's AIM market, announced it had raised a minimum of £12.9 million and up to £13.7 million through a subscription led by Singapore-based investor Eagle Eye Asset Holdings.
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?
Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year.
KEFI edges higher on Saudi minerals tie-up hopes
Shares in KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF, FRA:KMSA) rose 7% to 1.42p on Friday after the company responded to speculation around a possible new joint venture in Saudi Arabia. The AIM-quoted precious metals group, which is in the mine construction phase in Ethiopia, said its Saudi Gold and Minerals SLA (known as GMCO), in which it holds a 13% stake, is working with local conglomerate AJ Lan Group on a potential deal.
Artemis Resources drops as it heads for AIM exit
Artemis Resources Ltd (ASX:ARV, AIM:ARV, OTCQB:ARTTF, FRA:ATY) shares dropped around 20% on Thursday after it announced the cancellation of its AIM market admission, effective from 13 February 2026. The decision follows a review of the costs and benefits of maintaining the dual listing.
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?
Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Directa Plus shares slide 23% as cash falls and funding needs loom
Shares in Directa Plus PLC (AIM:DCTA, OTC:DTPKF) fell 23% to 10.44p after the AIM-listed graphene specialist flagged a sharp drop in cash and warned that fresh funding will be needed to support growth in 2026. The company said it expects full-year revenues of €7.0 million, up modestly from €6.66 million last year, with an adjusted loss before interest, tax, depreciation and amortisation of about €2.5 million.
